Manufacturer buying land downtown for expansion
A local maker of sterile vials and syringes has purchased a 1.5-acre parcel of land downtown to expand its life sciences operation.
Grand Rapids-based Grand River Aseptic Manufacturing, or GRAM, a parenteral contract manufacturer, said yesterday it signed a pair of purchase agreements to buy the lot on Butterworth Street SW at Tolford Avenue SW, about 100 yards from its facility at 140 Front Ave. SW.
“The substantial growth rate that we’ve experienced in the last several years has allowed us to match the needs of our clients and the industry,” said Tom Ross, president and CEO, GRAM. “With that growing demand, we are excited to add more manufacturing capacity, while remaining a quality-focused organization.”
The majority of the land was purchased from Grand Valley State University, and the rest was purchased from a private seller, according to a company spokesperson. The lot currently contains a vacant building.
Terms of the deals were not disclosed. The deals are expected to close within 90 days.
GRAM said it plans to break ground in mid to late summer on a new building on the parcel.
“As GRAM has grown and we have continued to add more capabilities, we’ve identified the need for more cleanroom space to serve our client’s needs and to meet the market demand in biologics and generic pharmaceutical markets,” said Nick Bykerk, VP of business development and finance, GRAM.
The new facility will house a cleanroom space, including new isolator technology, and high-speed, integrated manufacturing and packaging lines.
GRAM’s last expansion was in 2014 with the addition of a 28,000-square-foot facility that provided more warehousing space, as well as a place for finishing activities. That building is at 837 Godfrey Ave. SW.
Founded in 2011, Grand River Aseptic Manufacturing develops, makes, tests and provides regulatory filing support for sterile parenteral vials, syringes and other products for the life sciences and pharmaceutical industries.
Parenteral refers to medicinal solutions administered somewhere in the body other than the mouth or alimentary canal, including injections or infusions that are intravenous (into a vein), subcutaneous (under the skin) or intramuscular (into muscle).
The company has more than 160 employees.